Literature DB >> 11248491

Optimization of HPLC method for stability testing of bacitracin.

V Pavli1, V Kmetec.   

Abstract

A stability indicating HPLC assay for bacitracin has been developed and validated. The assay is based on a gradient elution, reversed phase column and UV diode array detection. On the basis of our previous analytical work several additional systematic HPLC tests for optimization of analytical method were performed. In order to achieve the highest selectivity of HPLC method, tests were conducted with extremely complex samples -- zinc bacitracin feed grade as food additive for animals. The influence of pH of mobile phase and type of columns on chromatographic separation of active (A, B(1) and B(2)) and inactive (F) polypeptide components of bacitracin were investigated in detail. It was found also that the peak B(1) comprises three and the peak F two subunits -- probably isomers. The obtained analytical procedure proved to be very selective and effective for the simultaneous determination of active polypeptide A, B(1) and B(2), impurities, known and unknown degradation products and ballast material.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11248491     DOI: 10.1016/s0731-7085(00)00569-0

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  3 in total

1.  High-resolution crystal structure reveals molecular details of target recognition by bacitracin.

Authors:  Nicoleta J Economou; Simon Cocklin; Patrick J Loll
Journal:  Proc Natl Acad Sci U S A       Date:  2013-08-12       Impact factor: 11.205

2.  Analysis of bacitracin and its related substances by liquid chromatography tandem mass spectrometry.

Authors:  Suleiman Ahmed Suleiman; Fan Song; Mengxiang Su; Taijun Hang; Min Song
Journal:  J Pharm Anal       Date:  2016-06-21

3.  Purification, characterization and in vitro anti-tumor activity of proteins from Arca subcrenata Lischke.

Authors:  Liyan Song; Shengfang Ren; Rongmin Yu; Chunyan Yan; Tingfei Li; Yu Zhao
Journal:  Mar Drugs       Date:  2008-07-10       Impact factor: 5.118

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.